Sotera Health

SHC

Market cap $4.65B

Sotera Health (SHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sotera Health (SHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sessa Capital increased its Sotera Health holding by 10,630,381 shares in the fourth quarter. The quarter-end position value rose by $206.47 million, reflecting both the share addition and stock price movement.

Inherent Management Corp. purchased 200,050 shares of Sotera Health in the fourth quarter. The quarter-end Sotera Health position value increased by $5.39 million as a result of the purchase.

Sotera Health Company (SHC) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript

CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today that it has appointed Kenneth D. Krause as a new independent director to its Board of Directors (the “Board”).

MIG Capital sold 2,262,292 shares of Sotera Health worth an estimated $37.41 million in the fourth quarter. Meanwhile, the quarter-end position value decreased by $31.83 million, reflecting both trading activity and share price movements.

Sotera Health Company (SHC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25 million shares of its common stock, par value $0.01 per share. All 25 million shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders.

Sotera Health (SHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.